Contact us
Contact us


by Feldan Therapeutics on Feb 9,2021

Québec, Canada, February 9, 2021 – Feldan Therapeutics, a biotechnology company that develops therapeutics based on the intracellular delivery of proteins and peptides, announces the appointment of Dr. David J. Mazzo and Dr. Iain D. Dukes as independent members of its board of directors.

“We are pleased to welcome Drs. Mazzo and Dukes to our board. They are two highly accomplished biopharmaceutical executives who bring many years of operational, strategic and financing expertise to Feldan,” said François-Thomas Michaud, co-founder and chief executive officer of Feldan. “The addition of these two directors complements our board of directors’ skills and experience, and will provide valuable guidance and vision as Feldan moves toward its first CTA/IND filing and next round of financing.”

About Dr. David J. Mazzo
Dr. Mazzo is a pharmaceutical executive and strategic leader with more than 35 years of broad international experience developing and launching drug products for both big pharma and emerging pharma in the U.S., Canada, Europe and Japan. He is also a seasoned board director, having served on the boards of all the companies for which he was CEO, as well as Essex Chemie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals and EyePoint Pharmaceuticals, where he served as chairman of the board until 2018. Dr. Mazzo is the current chairman of the board of Visioneering Technologies, Inc.

Dr. Mazzo earned a Ph.D. in Analytical Chemistry and an M.S. in Chemistry from the University of Massachusetts (Amherst), and he completed a research fellowship at the École Polytechnique Fédérale de Lausanne (Switzerland). He also holds a B.S. (Chemistry) and a B.A. (Honors – Interdisciplinary Humanities) from Villanova University (Pennsylvania).

About Dr. Iain D. Dukes
Dr. Dukes is a Venture Partner at OrbiMed Advisors. He previously served as Senior Vice-President and Head of business development and licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. Dr. Dukes has also served as President and CEO, and a member of the Board of Directors, of Essentialis Therapeutics, a clinical-stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice-President of Scientific and Technology licensing at GlaxoSmithKline, and prior to that, he held various positions at Glaxo Wellcome, including head of exploratory development for metabolic and urogenital diseases and head of the Ion Channel Drug Discovery Group. Dr. Dukes is Chaiman of Iovance Biotherapeutics (NASQ: IOVA) and serves on the Board of Directors of Themis Biosciences (acquired by Merck & Co), Ikena Oncology, KaNDy Therapeutics (previously as Chairman, acquired by Bayer AG), NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics.

Dr. Dukes co-founded and is Chief Executive Officer of Theseus Pharmaceuticals; co-founded and serves on the Board of Directors of Kartos Therapeutics where he is President; and co-founded Telios Pharma, where he is President and serves on the Board of Directors. He is also Executive Chairman of Angiex.

Dr. Dukes holds an M.A. and D.Phil, from the University of Oxford, an MSc. in Cardiovascular Studies from the University of Leeds, and a B.Sc. in Pharmacology from the University of Bath.

Feldan’s Board of Directors includes:
Benoit Cyr, M.Sc, Eng. – Executive Chairman, Feldan Therapeutics
Sungyong Won, Ph.D. – General Manager, Corporate Development and Investment Division, GC Holdings
Hyun-Ki Kim, M.Sc. – Managing Director, Stonebridge Ventures
Robert J. Wills, Ph.D. – Chairman, CymaBay Therapeutics
Paul Truex, MBA – Chairman of the Board, LQT Therapeutics, and Board Member, Milestone Pharmaceuticals
David J. Mazzo, Ph.D. – President and Chief Executive Officer, Caladrius Biosciences, Inc.
Iain D. Dukes Ph.D. – Venture Partner, OrbiMed Advisors
Jean De Serres, MD. – VP Scientific Affairs and Operations, Paladin Labs
François-Thomas Michaud, Ph.D., Eng. – Co-founder and Chief Executive Officer, Feldan

About Feldan:
Feldan specializes in the development of treatments based on the intracellular delivery of proteins and peptides, with a therapeutic pipeline focused on diseases affecting lungs and skin. The company is behind the design of a proprietary peptide-based intracellular delivery technology that enables safe and efficient intracellular delivery of multiple therapeutic compounds and unlocks the development of a new generation of therapies.

For more information:

Contact: François-Thomas Michaud, Ph.D. Eng.
Chief Executive Officer
Feldan Therapeutics, Inc.
T: +1 418-872-7277